WHO identified Visceral Leishmaniasis (VL) as a Category I disease (emerging and uncontrolled) and the support to the Elimination control programs in India, Nepal and Bangladesh were intensified in 2005. One of the key approaches that allows accelerated efforts towards the elimination process is by focusing on availability, affordability and accessibility of medicines used to treat VL. This presentation by Ms. Aishwarya Kulkarni, who has completed her BPharm, focuses on the evolution of the medicines for VL, their prices and some of the current issues in this regard.
3.00 pm – 4.00 pm
Institute of Public Health, Bengaluru
#250, 2nd C Main, 2nd C Cross,
Girinagar Ist Phase,
Bengaluru – 560085